KOSDAQ and Global Bio ETFs: Rising Volatility and Underperformance
The KOSDAQ exchange-traded fund (ETF) market has recently experienced significant volatility, prompting asset managers to hold emergency meetings. The stock price of Samchundang Pharm plummeted over 59% due to controversy over a licensing agreement with a US partner, resulting in major losses of 13% to 15% for KOSDAQ active ETFs heavily weighted in the stock. Losses were especially pronounced in bio sector-focused ETFs, and a portfolio strategy concentrating on large-cap growth stocks exacerbated underperformance. Despite continued capital inflows, management companies are strained by worsening returns and declining investor confidence.
Meanwhile, bio stocks have shown high sensitivity to analyst reports and market commentary, leading to increased instability; in some cases, share prices soar or crash based on reports from securities firms. Experts advise that investors should thoroughly analyze individual company performance and market conditions before investing in ETFs. On the global stage, bio ETFs continue to struggle; however, China’s bio sector is rebounding. Notably, Samsung Active Asset Management’s China Bio ETF is outperforming, surpassing passive products in both returns and cost efficiency.
Related News
조선일보18 hours ago
KOSDAQ Active ETF with 1 Trillion Won from Individual Investors… Performance Over a Month Was Worse Than KOSDAQ - Chosun IlboLast month, over 1 trillion won from individual investors flowed into the first-ever KOSDAQ Active ETF listed in Korea, but its returns significantly underperformed compared to the KOSDAQ index. Active ETFs are indices
조선일보18 hours ago
"Afraid to Write Reports"... K-Bio Stocks Wobble on Rumors, ETFs also in 'Negative Quagmire'Afraid to write reports, K-Bio stocks are wobbling on rumors, and ETFs are also in a negative quagmire. Even the number one on KOSDAQ is hitting rock bottom at an analyst's word. Leading biotech stocks such as Alteogen and Samchundang Pharmaceuticals, which are among the top in KOSDAQ market capitalization, are swaying significantly at just a single word from securities analysts. New drugs are prioritized over performance.
딜사이트19 hours ago
[ETF Matchup] Chinese Bio Rebounded During War... Samsung Active > Mirae Asset - Deal SiteWhile global stocks fall... Chinese bio theme differentiates with double-digit returns, KoAct 11.3%
Money Poured in but Returns Fell: Struggling KOSDAQ ETFDespite the influx of funds, the returns of the KOSDAQ ETF have fallen significantly. An actively managed ETF initially sized at 200 billion won attracted over 1 trillion won from retail investors, but returns are hindered due to market volatility concerns.
Kosdaq Active ETF 'Scream' Hit by Samchundang PharmThe Kosdaq active exchange-traded fund (ETF), which gained popularity riding on the expectations of 'Samcheonsdaq' (Kosdaq index 3000), was directly hit by the plunge in Samchundang Pharm's stock price.
Scream in KOSDAQ Active ETF Bitten by Samchundang Pharm - Kookmin DailyThe KOSDAQ Active Exchange Traded Fund (ETF), which gained popularity riding on the expectation of 'Samchunstock' (KOSDAQ Index 3000), has been directly hit by the plummeting stock price of Samchundang Pharm. Related ETF product